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We present the synthesis and characterization of a highly efficient thorium chelator, derived from the
octadentate hydroxypyridinone class of compounds. The chelator forms extremely stable complexes with
fast formation rates in the presence of Th-227 (ambient temperature, 20 min). In addition, mouse
biodistribution data are provided which indicate rapid hepatobiliary excretion route of the chelator
which, together with low bone uptake, supports the stability of the complex in vivo. The carboxylic acid
group may be readily activated for conjugation through the e-amino groups of lysine residues in biomo-
lecules such as antibodies. This chelator is a critical component of a new class of Targeted Thorium
Conjugates (TTCs) currently under development in the field of oncology.
 2016 Bayer AS. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The clinical development of targeted radioimmunotherapies
(RIT) for the treatment of cancer utilizing the high linear energy
transfer (LET) of alpha-particles has, to a large extent, been limited
by the availability of suitable radionuclides on a commercial scale.
More recently, with the approval in May 2013 of Xofigo for the
treatment of castration resistant prostate cancer (CRPC),1 a com-
mercial production line for the alpha-emitting radionuclide
radium-223 (Ra-223) was established. However, although the
inherent bone-seeking characteristics of Ra-223 make it well
suited for the targeting of bone metastases in CRPC, the paucity
of efficient chelator systems limits its use in radioimmunotherapy.
By utilizing the same actinium-227 generators as used in the man-
ufacture of Ra-223,2 highly purified thorium-227 (Th-227) may be
produced. Unlike Ra-223, Th-227 exists in the 4+ oxidation state
and forms stable complexes with chelators such as 1,4,7,10-tetra-
azacycloododecane-N,N0,N00,N000-tetraacetic acid (DOTA). However,
in order to achieve sufficient labeling of DOTA-coupled antibodies,
the complexation step must either be performed as a two-step pro-
cess3 or directly at elevated temperatures.4 The harsh conditions
used for direct labeling are not always compatible with the stabil-
ity of complex biological macromolecules such as antibodies. In
addition the slower complex formation rates affect radiolabeling
yield, efficiency and specific activity.5
Therefore, there remains a need for alternative chelators which
complex thorium-227 in near quantitative yield at ambienttemperature in aqueous solutions. To this end we have developed
an octadentate chelator utilizing the 3-hydroxy-N-methyl-2-
pyridinone moiety, abbreviated henceforth as Me-3,2-HOPO,
reported previously to form extremely stable thorium com-
plexes.6,7 The Me-3,2-HOPO groups are monoprotic acids that com-
plex thorium-227 through the two oxygen atoms on each subunit.8
Figure 1 shows the structural drawing of the target octadentate
Me-3,2-HOPO thorium-227 complex 1. We report herein on the
synthesis, labeling and in vivo biodistribution in mice and provide
evidence of superiority of this new chelator compared to DOTA for
thorium-227 complexation.
The chelator comprises three key components. The Me-3,2-
HOPO moiety, which complexes the thorium; a symmetrical poly-
amine scaffold to which the Me-3,2-HOPO moieties are coupled;
and a carboxylic acid group facilitating conjugation to biomole-
cules such as antibodies.
Scheme 1 shows the synthesis of the polyamine scaffold com-
ponent. Compound 3 was isolated in 66% yield by the addition of
4-nitrobenzyl bromide to a mixture of dimethyl malonate/NaH in
tetrahydrofuran (THF). Diisobutylaluminium hydride (DIBAL-H)
reduction in THF was performed to generate diol 4 in 46% yield.
Care was taken to stop the reaction before completion to avoid
reduction of the nitro group. Activation by mesylation of 4 with
methane sulfonyl chloride and triethylamine in dichloromethane
(DCM) gave compound 7, the crude material after workup being
used directly in the next step. The bis-Boc protected triamine 6
was formed in 56% yield from diethylenetriamine 5, directly using
N-Boc-imidazole. The fully protected precursor was prepared in
Scheme 2. The synthesis route to the activated Me-3,2-HOPO precursor.
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Figure 1. Drawing of the octadentate hydroxypyridinone thorium-227 complex 1.
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propylethylamine (DIPEA) as base. Finally, the deprotected product
9 was isolated in 66% yield by addition of sulfuric acid to com-
pound 8 in methanol.
Scheme 2 shows the synthesis of the activated Me-3,2-HOPO
precursor. Construction of building block 11 poses the challenge
of correctly introducing the functional group in the 4-position of
the dihydropyridine ring. One approach, previously reported by
Xu et al. relied on the carboxylation of 1-methyl-3-hydroxy-2-
pyridinone at 5860 kPa/CO2.9 We have investigated an alternative
method employing condensation of 2-pyrrolidinone with diethyl
oxalate which also yields the correctly substituted tetrahydropy-
ridine-4-carboxylate through a sequential ring-opening and clo-
sure under Claisen conditions.10 In the first step, the reaction
between 2-pyrrolidinone and diethyl oxalate gives compound 11 
Scheme 1. The synthesis route to the polyamine scaffold.in 73% yield. Subsequent aromatization using Pd/C has been
described previously and results in a 75% yield of 12.11 N-methyla-
tion was then performed with an excess of methyl iodide and
potassium carbonate. This reaction resulted in the formation of
the methyl ether as well as partial trans-esterification. The O-
methyl group was removed using BBr3 in dichloromethane
(DCM) and following quenching and isolation by filtration 14
was treated with benzyl bromide furnishing the desired benzyl
ether 15. Further transesterification occurs in this reaction; the
combined yield of all three esters being 67%. Ester hydrolysis
was then carried out in methanol/water with NaOH, giving car-
boxylic acid 16 in 89% yield. Finally conversion of the carboxylic
acid with 2-thiazoline-2-thiol with N,N0-dicyclohexylcarbodiimide
and 4-dimethylaminopyridine was performed in dichloromethane
yielding the thiazolidino-activated and benzyl protected Me-3,2-
HOPO building block 17 in 87% yield.
Scheme 3 details the synthesis of the octadentate Me-3,2-HOPO
chelator compound 21. By simply stirring compounds 9 and 17 in
DCM for 16–20 h the protected chelate 18was formed in 68% yield.
Reduction of the nitro group to the amine 19 with iron/NH4Cl, fol-
lowed by removal of the benzyl protecting groups with BBr3 gave
the desired product 20 in 90% yield. In the final step, compound
21 was formed by reaction with succinic anhydride as shown in
Scheme 3. On removal of the benzyl protecting groups care was
taken to avoid contamination of the chelate system with unwanted
metal ions. Both compounds 20 and 21, complex a variety of met-
als with oxidation states of +2, +3 and +4 and in particular show
high affinity for ferric ions. Complex formation and characteriza-
tion was confirmed by LC–high resolution mass spectrometry
using non-radioactive thorium-232 as surrogate. The full details
of the synthesis and characterization steps are given in Supporting
information.
Conjugation of compound 21 to monoclonal antibodies is
described in detail elsewhere.12 However, the chemistry is robust
and reproducible. Briefly, the in situ pre-activation of compound
21 is performed in 4-morpholinoethanesulfonic acid (MES) buffer
pH 5.5 in the presence of 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide and N-hydroxysuccinimide.13 The activated chelator is
then added to a solution of the antibody in phosphate-buffered sal-
ine (PBS) at pH 7.4 with gentle mixing for 30 min before purifica-
tion of the conjugate.
Scheme 3. The synthesis route to the octatendate Me-3,2-HOPO thorium chelator, compound 21.
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pound 21 with thorium-227 (synthesis of complex 1) as well as
the pharmacokinetics of complex 1 in mice. In a typical labeling
experiment14 compound 21 is added directly to a solution of tho-
rium and the complexation allowed to proceed for 30 min. Com-
plex 1 as the test item for injection had a final chelator
concentration of 0.0125 mg/mL (target; 0.0125 mg/mL), specific
activity of 14082 kBq/mg (target 14000 kBq/mg, and thorium con-
centration of 188 kBq/mL (target 175 kBq/mL). An aliquot of the
chelate complex was analysed by iTLC, the strips were divided into
two halves and counted separately in a high performance germa-
nium detector. Free Th-227 is known to migrate with the solvent
front while chelated Th-227 remains at the application point. In
this example >96% of the measured activity remained at the appli-
cation point.
The blood clearance and tissue distribution of complex 1 in
female C57Bl6 mice was studied (Table 1). Animals were adminis-
tered complex 1 as a single slow bolus injection via the tail vein.
The dose volume was 5 mL/kg (0.1 mL/20 g mouse), the target dose
of complex 1 was 0.05 mg/kg, and for the radioactivity, 700 kBq/kg
thorium-227. Animals were sacrificed at the following post-treat-
ment time-points; 5 min, 1 and 4 h and on days 1, 3 and 7. Samples
of blood and tissues were collected and the radioactivity measured
on a high performance germanium detector. Activity was decay
corrected to give the activity at time of sampling/euthanasia.Complex 1 rapidly cleared from the blood, with t½ alpha
approximately 0.4–1 h, and t½ beta in the range of 4.9–6.4 h, with
almost complete elimination from the blood at 24 h. At the early
time points the presence of complex 1 was observed mainly in
the liver and small intestine with measured doses of 7.2% and
14.4%ID/g respectively after only 5 min. After 4 h the large intes-
tine had a measured dose of 48%ID/g, indicating that the route of
excretion was predominant biliary, consistent with the hydropho-
bic nature of complex 1. Although our ultimate aim is to develop
antibody-based targeted thorium conjugates with this chelator
system, it is important to know the fate of any free complex 1
formed as a result of metabolic cleavage of the chelate from the
antibody in vivo. We anticipate the rapid excretion of free labeled
chelate through the liver will minimize the potential off-target tox-
icity of this potential metabolite.
It has been previously observed by ourselves and others that
free thorium-227 has bone-seeking properties, with the highest
uptake rates in the skeleton. Washiyama et al. demonstrated that
following injection of thorium-227 citrate in mice 28.4 and 19.4%
ID/g was measured in the femur after 1 and 7 days, respectively.15
In this study we hypothesized that any instability of the complex
in vivo would be reflected in high bone uptake values. The finding
on days 1, 3 and 7 that femur uptake was measured at 1.8, 1.9 and
1.4%ID/g, respectively, consistent with in vivo stability of the com-
plex 1.
Table 1
Organ distribution of complex 1 as % injected dose per gram (%ID/g) post injection
Th-227 (%ID/g)
Time 5 min 1 h 4 h Day 1 Day 3 Day 7
Organ Average
(n = 3)
SD Average
(n = 3)
SD Average
(n = 3)
SD Average
(n = 3)
SD Average
(n = 3)
SD Average
(n = 3)
SD
Blood 3.2 0.9 1.1 0.5 0.2 0.1 0.02 0.00 0.00 0.01 0.00 0.00
Lung 3.9 2.4 0.7 0.06 0.2 0.1 0.10 0.02 0.08 0.01 0.12 0.05
Liver 7.2 4.2 1.9 0.4 1.3 0.4 1.08 0.20 0.91 0.06 0.83 0.17
Spleen 1.28 0.57 0.37 0.06 0.13 0.10 0.29 0.06 0.33 0.09 0.39 0.16
Kidney 3.89 2.11 1.99 0.3 1.73 1.04 2.26 0.38 1.66 0.08 1.37 0.29
Large Intestine + contents 0.97 0.60 12.0 19.9 48.1 19.4 0.22 0.06 0.04 0.00 0.05 0.01
Small Intestine + contents 14.4 12.2 37.8 14.4 6.83 2.11 0.10 0.02 0.04 0.00 0.04 0.01
Heart 1.61 0.72 0.32 0.03 0.14 0.12 0.08 0.01 0.07 0.01 0.09 0.02
Femur 2.17 1.47 1.40 0.35 0.33 0.15 1.81 0.21 1.94 0.61 1.43 0.53
Residual carcass 1.08 0.26 0.84 0.26 0.36 0.24 0.14 0.02 0.13 0.00 0.12 0.03
Tail 49.9 45.4 25.5 24.4 16.5 1.98 0.92 0.60 0.31 0.53 1.39 0.72
T. Ramdahl et al. / Bioorg. Med. Chem. Lett. 26 (2016) 4318–4321 4321In conclusion, the discovery of new chelator systems that
efficiently complex Th-227 with sufficient in vivo stability is a pre-
requisite for the development of antibody targeted alpha-pharma-
ceuticals. The optimal chelator characteristics are governed by the
long half-life of Th-227 (18.7 days) coupled to the long biological
half-life of the antibody in vivo. The high Relative Biological Effec-
tiveness of the alpha particle potentially allows for therapeutic effi-
cacy at lower radiation doses compared to beta-emitters16,17 as the
decay of Th-227 releases in total 5 alpha-particles with a total
alpha energy of 32.5 MeV.18 We provide evidence in this report
that compound 21 is an efficient chelator of Th-227 and is a supe-
rior chelator to DOTA as it requires no heating to effect efficient
labeling. In addition the octadentate Me-3,2-HOPO, compound
21, demonstrates rapid complexation, which is a key requirement
for the future commercial development of thorium-227 based
alpha-pharmaceuticals.
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmcl.2016.07.
034.
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